Repligen Corporation (NASDAQ:RGEN) Shares Acquired by Fox Run Management L.L.C.

Key Points

• Fox Run Management L.L.C. increased its holdings in Repligen Corporation by 306.6%, owning 18,848 shares valued at approximately $2.40 million, making Repligen its 18th largest position.
• Analysts' ratings for Repligen shares vary, with a consensus rating of "Moderate Buy" and an average price target of $169.45, despite some recent reductions in price targets.
• Repligen reported a 14.8% year-over-year revenue increase with $182.37 million in revenue for the last quarter, although it missed EPS estimates by $0.03.

Fox Run Management L.L.C. boosted its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 306.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,848 shares of the biotechnology company's stock after acquiring an additional 14,213 shares during the period. Repligen accounts for 0.4% of Fox Run Management L.L.C.'s holdings, making the stock its 18th biggest position. Fox Run Management L.L.C.'s holdings in Repligen were worth $2,398,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of RGEN. Neuberger Berman Group LLC acquired a new position in shares of Repligen in the first quarter valued at about $693,000. Caitong International Asset Management Co. Ltd boosted its position in Repligen by 421.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,992 shares of the biotechnology company's stock valued at $253,000 after buying an additional 1,610 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Repligen by 44.2% in the 1st quarter. Russell Investments Group Ltd. now owns 83,874 shares of the biotechnology company's stock worth $10,672,000 after buying an additional 25,702 shares during the period. Westpac Banking Corp increased its holdings in Repligen by 31.0% in the 1st quarter. Westpac Banking Corp now owns 28,456 shares of the biotechnology company's stock worth $3,621,000 after buying an additional 6,731 shares during the period. Finally, HighTower Advisors LLC raised its position in Repligen by 15.3% during the 1st quarter. HighTower Advisors LLC now owns 5,828 shares of the biotechnology company's stock worth $742,000 after buying an additional 774 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on RGEN shares. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 target price for the company in a report on Tuesday, July 22nd. Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Royal Bank Of Canada raised their price objective on shares of Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 30th. Evercore ISI dropped their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research report on Tuesday, July 8th. Finally, Wells Fargo & Company decreased their price objective on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $169.45.

Insider Activity

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were purchased at an average cost of $112.13 per share, with a total value of $201,834.00. Following the completion of the purchase, the director owned 1,800 shares in the company, valued at approximately $201,834. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 1.20% of the stock is owned by insiders.

Repligen Price Performance

Repligen stock traded down $2.29 during midday trading on Friday, reaching $124.35. The company had a trading volume of 574,823 shares, compared to its average volume of 1,060,907. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The company has a market capitalization of $7.00 billion, a P/E ratio of -497.38, a P/E/G ratio of 2.29 and a beta of 1.05. The firm's fifty day simple moving average is $122.50 and its 200-day simple moving average is $132.73.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. During the same quarter last year, the business earned $0.40 EPS. The business's revenue was up 14.8% compared to the same quarter last year. As a group, equities analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.